Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Compounds Show Promise in Fighting Malaria and Cancer

25.08.2004


Using an ancient Chinese folk remedy as a model, researchers at The Johns Hopkins University in Baltimore have designed several new compounds that, in early testing, promise to be both safer and more effective in fighting malaria and some forms of cancer than the current “gold standard” drug treatments.

Scientists will announce their successful results in late August at the American Chemical Society’s annual summer meeting, held this year in Philadelphia. Some of the results also appeared in the January 2004 issue of the Journal of Medicinal Chemistry. “Preliminary data show that our laboratory-synthesized compounds have a therapeutic index – the measure of a drug’s safety and efficacy – that is better, in some cases, many times better, in rodents than the drugs currently considered the gold standard for chemotherapy of both malaria and prostate cancer,” said Gary Posner, Scowe Professor of Chemistry in the Krieger School of Arts and Sciences at Johns Hopkins. “These results are preliminary, but exciting, and certainly worth pursuing.”

Malaria afflicts between 300 million and 500 million people a year, killing between 1.5 million and 3 million of them – mostly children. Spread by female mosquitos feeding on human blood, the most commonly fatal strain of the malaria parasite began showing formidable resistance to current treatments decades ago, making the development of new and more effective drugs a worldwide priority.



With support from the National Institutes of Health since 1994, Posner’s research team, which also includes Theresa Shapiro, professor of clinical pharmacology at the Johns Hopkins School of Medicine, tackled that challenge by designing a series of compounds called trioxanes. These compounds are aimed at mimicking the mechanism of action of artemisinin, the active agent in the Artemisia annua plant, which has been used in China as an herbal remedy for malaria and other fevers for thousands of years.

Posner’s research and that of other laboratories revealed that the peroxide (oxygen-oxygen) unit within artemisinin and within other antimalarial trioxane drugs causes the malaria parasites to self-destruct. “We know that the malaria parasites digest hemoglobin in order to get nutrients, and in the process they release heme,” Posner explained. “When the heme encounters the peroxide bond, a chemical reaction occurs. Powerful chemical species such as carbon-free radicals and oxidizing agents are produced, harming and eventually killing the parasites.”

In the laboratory, several of the Posner trioxane compounds were compared against sodium artesunate – the gold standard for malaria treatment – in rodents. Administered intravenously, two of the new compounds outperformed the gold standard. “One was six or seven times better, and the other was three or four times more effective, which is substantial,” Posner said. “What’s more, when the trioxanes were administered orally, it was found that one of ours is four times more effective. That’s significant.”

Lab testing also revealed that at least one of the trioxane compounds – known as compound 7 – seems to be even safer than sodium artesunate. Testing of the Johns Hopkins trioxanes in rodent models for human prostate cancer in collaboration with the Roswell Park Cancer Institute in Buffalo, N.Y., was equally encouraging to the researchers, who are promoting the compounds as dual-use drug candidates.

In that laboratory, researchers pitted the potency of the trioxane compounds against two gold standard anticancer drugs, Gemzar and Adriamycin. They found that while trioxane compound 6 was comparable to the cancer-fighting action of Adriamycin, compound 5 appears to be nearly three times more powerful than that drug. “Our learning from this is that trioxane dimers 5 and 6, and especially 6, are exciting not just for their antimalarial potential, but also for their anticancer potential,” Posner said.

| newswise
Further information:
http://www.jhu.edu

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>